Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/49734
Title: Pioglitazone: Beyond glucose control
Authors: De Pablos-Velasco, Pedro 
Keywords: Type-2 Diabetes-Mellitus
Congestive-Heart-Failure
Adverse Cardiovascular Events
Intima-Media Thickness
High-Risk Patients, et al
Issue Date: 2010
Publisher: 1477-9072
Journal: Expert Review of Cardiovascular Therapy 
Abstract: Pioglitazone is an oral antidiabetic agent that decreases insulin resistance in adipose tissue, liver and muscles. This action is mediated by its link to a nuclear receptor called peroxisome proliferator-activated receptor-gamma. By improving insulin sensitivity, hepatic glucose production decreases and glucose uptake increases in the peripheral tissues. Beyond these effects on glucose metabolism, pioglitazone has positive effects on lipid metabolism, blood pressure, endothelial function, adiponectin and C-reactive protein levels. These make pioglitazone treatment effective beyond glucose control. In this article, current evidence concerning pioglitazone in the treatment of Type 2 diabetes will be reviewed.
URI: http://hdl.handle.net/10553/49734
ISSN: 1477-9072
DOI: 10.1586/ERC.10.98
Source: Expert Review of Cardiovascular Therapy[ISSN 1477-9072],v. 8, p. 1057-1067
Appears in Collections:Artículos
Show full item record

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.